T
Talaris Therapeutics
Talaris Therapeutics is a therapeutic based company
About Talaris Therapeutics
Talaris Therapeutics, Inc. was a late-clinical stage cell therapy company founded in 2002 by Suzanne Ildstad, a transplant surgeon and professor at the University of Louisville. Initially known as Regenerex, the company was built upon Ildstad's pioneering research into facilitating cells, a specific type of cell discovered in 1990 that helps donor stem cells engraft in the bone marrow and thrive, potentially eliminating the need for lifelong immunosuppressant drugs for transplant recipients. The company's work was based on technology patented and licensed from the University of Louisville.
The company's primary business was the development of its lead product candidate, FCR001, an allogeneic cell therapy. This therapy was designed for patients receiving organ transplants, particularly from living kidney donors, and for those with severe autoimmune diseases like scleroderma. The goal was to induce durable immune tolerance, allowing patients to live without the daily regimen of immunosuppressive drugs that carry significant toxicities and shorten lifespan. After showing promise in a Phase 2 trial where 70% of kidney transplant patients were weaned off immunosuppressants, the company attracted significant investment. A key milestone was a $100 million Series A funding in 2019 led by Blackstone's life sciences arm, which also saw the company rebranded as Talaris Therapeutics and the appointment of Scott Requadt as CEO. This was followed by a $115 million Series B in 2020 and a $150 million IPO two years later to advance FCR001 into Phase 3 testing.
Despite the promising science, Talaris faced significant setbacks. In 2022, a patient death in its Phase 3 FREEDOM-1 trial, due to graft-versus-host disease (GvHD), triggered a temporary halt. Although the trial resumed, slow enrollment and extended timelines led to the decision in February 2023 to discontinue the kidney transplantation programs entirely. This resulted in a corporate restructuring, a reduction of its workforce by a third, and a strategic review to maximize shareholder value. The company's focus narrowed to a Phase 2 trial for scleroderma while exploring options like a merger or sale. Ultimately, in June 2023, Talaris entered into a definitive reverse merger agreement with Tourmaline Bio, a private biotechnology company. The merger was completed in October 2023, with the combined entity operating under the Tourmaline Bio name (Nasdaq: TRML) and focusing on Tourmaline's lead asset, TOUR006, for immune disorders. Talaris ceased independent operations, with its stock being delisted.
Source: Dealroom company dataNews
Open roles
Talaris Therapeutics in the Louisville ecosystem
The Talaris Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Blackstone
Qiming Venture Partners USA
Longitude Capital
Viking Global Investors
Citadel
Cormorant Asset Management
BlackRock
Invus
Eventide Asset Management
Logos Capital
Aisling Capital
Pamoja Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Talaris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Talaris Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


